Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Osteoporosis
Interventions: DRUG: Zoledronic Acid|DRUG: Letrozole
Sponsor: Novartis Pharmaceuticals